Perrigo signs agreement to divest Tysabri® royalty stream for up to $2.85 billion
Perrigo announced an agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri® (natalizumab) to RPI Finance Trust, an affiliate of Royalty Pharma. This transaction is valued at a total of up to $2.85 billion. February 27, 2017